News – Page 1092 – Endpoints News

The FDA's insider view on Aerie’s glaucoma drug: Yes on efficacy, but…

8 years ago

Ten big lobbying groups turn their guns on Allergan's controversial patent gambit

8 years ago

Shooting for PhIII, Spero tees up a new lead antibiotic in-licensed cheap as it lines up $86M IPO

8 years ago

Former FDA chief von Eschenbach steps up his advisory role at Malin

8 years ago

With just a little encouragement, biotech investors are ready to fall in love again

8 years ago

Scott Gottlieb likes his job running the FDA, but he isn't ruling out a big HHS promotion

8 years ago

India’s Lupin bags Symbiomix and its newly approved antibiotic for $150M-plus

8 years ago

Deerfield commits $50M-plus to translational drug R&D at the Broad

8 years ago

Amgen catches a break as FDA rejects Neulasta knockoff; Zafgen gets a new CEO as Hughes moves to top science job

8 years ago

Giant Merck buddies up with little KalVista on lead drug, igniting stock with a $760M deal

8 years ago

AbbVie jumps on the oncolytics bandwagon, embracing Turnstone in new collaboration

8 years ago

Eli Lilly concedes a PhIII flop for abemaciclib as breakout strategy flounders

8 years ago

Spark Therapeutics faces a grilling as FDA ponders a pioneering OK for gene therapy

8 years ago

Abbas Hussain swings from top GSK pharma post to powerhouse Chinese private equity player C-Bridge

8 years ago

Biotech scientist/entrepreneur Saurabh Saha makes an unusual return to the arms of a big — and excessively discreet ...

8 years ago

Third Rock-backed Allena looks to springboard a $92M IPO off of a failed PhIIb

8 years ago

Flexion nabs FDA OK for its potential blockbuster osteoarthritis drug, triggering new buyout buzz

8 years ago

AstraZeneca’s next big cancer drug linked to falsified preclinical data; Harmony raises $270M, nabs development ...

8 years ago

David Meeker starts a new biotech chapter in his career; Sam Kulkarni takes the helm at CRISPR

8 years ago

Third Rock, SV bankroll another PhI/II for a new, improved and jab-free wet AMD drug

8 years ago

'Going big': Merck launches frontline PhIII lung cancer study for Keytruda/Yervoy combo

8 years ago

Facing an exodus, EMA starts to line up temp replacements as top staffers jump ship

8 years ago

In a setback, Bayer, J&J say their big PhIII secondary stroke trial for Xarelto failed

8 years ago

Allergan shows how you can destroy your rep and get mobbed by lawmakers in 4 easy steps

8 years ago

First page Previous page 1089 1090 109110921093 1094 1095 Next page Last page